Background/aim: The aim of this study was to evaluate the efficacy and safety of carboplatin/docetaxel combination therapy in patients with locally advanced and/or recurrent/metastatic (LA/RM) salivary gland carcinoma (SGC).
Materials And Methods: This was a retrospective analysis of 24 patients that included six patients with AR-positive salivary duct carcinoma (SDC) after progressive disease treated with combined androgen blockade (CAB). Carboplatin (AUC5) and docetaxel (70 mg/m) were administered for six courses every three weeks.
Results: The overall response rate was 42%, the median progression-free survival was 8.4 months, and the median overall survival was 26.4 months. Among the six patients with CAB-resistant SDC, two achieved a partial response and two long-term stable disease. Grade 3/4 neutropenia and anemia were observed in 20-30% of the patients; all adverse events were manageable.
Conclusion: Carboplatin/docetaxel combination therapy may be a chemotherapeutic option for patients with LA/RM SGC, and a valuable second-line chemotherapy for CAB-resistant, AR-positive SDC.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6559918 | PMC |
http://dx.doi.org/10.21873/invivo.11549 | DOI Listing |
RMD Open
January 2025
Rheumatology and Clinical Immunology, University of Groningen, University Medical Centre Groningen, Groningen, Groningen, The Netherlands.
Objectives: The objectives are to evaluate variation in systemic disease activity (European Alliance of Associations For Rheumatology (EULAR) Sjögren's Syndrome Disease Activity Index (ESSDAI)) over time at group and individual patient level and to assess associations of ESSDAI low disease activity (LDA) with other outcome measures in a standard-of-care cohort of patients with Sjögren's disease (SjD).
Methods: Patients with SjD participating in a prospective longitudinal study (REgistry of Sjögren Syndrome LongiTudinal cohort) fulfilling the 2016 American College of Rheumatology/EULAR classification criteria with ≥2 years of follow-up were included. ESSDAI was assessed at least yearly, up to 5 years.
J Physiol Sci
January 2025
Division of Pharmacology, Meikai University School of Dentistry, 1-1 Keyakidai, 350-0283, Sakado, Saitama, Japan.
This in vivo mouse model study was conducted to investigate the temporal alteration of the function of CD36 in salivary secretion. CD36 was highly expressed in the parotid gland of BALB/c mice. No significant variations were shown in the CD36 levels in the 8-, 48-, and 72-week-old animals.
View Article and Find Full Text PDFBMJ Case Rep
January 2025
Division of Plastic and Reconstructive Surgery, Department of Surgery, Faculty of Medicine Vajira Hospital, Navamindradhiraj University, Bangkok, Thailand
Schwannomas, benign tumours derived from Schwann cells, exhibit slow growth rates and are commonly found extracranially in the head, neck and extremities. However, intraoral and salivary gland schwannomas are less frequent. Ancient schwannomas, characterised by histological degenerative changes, represent a rare variant.
View Article and Find Full Text PDFBMJ Case Rep
January 2025
Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Salivary gland malignancies are rare, accounting for less than 5% of head and neck cancers. Mucoepidermoid carcinoma (MEC) is the most common salivary gland tumour, predominantly found in the parotid gland. However, it has rarely been reported in the tongue.
View Article and Find Full Text PDFJ Agric Food Chem
January 2025
State Key Laboratory for Biology of Plant Diseases and Insect Pests, Institute of Plant Protection, Chinese Academy of Agricultural Sciences, Beijing 100193, China.
is a highly polyphagous pest that causes substantial agricultural damage. Temperature and insecticides are two major abiotic stresses affecting their population abundance. Heat shock proteins play an essential role in cell protection when insects are exposed to environmental stresses.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!